为您找到相关结果约25个

你是不是要搜索 期刊Bempeg 点击跳转

Bempeg Failure Unlikely to Affect Other IL2 Drugs

agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG

between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG

PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO

Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated

Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated

PROGRESSION-FREE SURVIVAL AND BIOMARKER CORRELATES OF RESPONSE WITH BEMPEG PLUS NIVO IN PREVIOUSLY UNTREATED

PIVOT-12: A phase 3 randomized study of adjuvant bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs

administered in combination with nivolumab (NIVO) with or without ipilimumab (IPI) or bempegaldesleukin (BEMPEG

1b/2 study of BXCL701, a small molecule inhibitor of dipeptidyl peptidases, with bempegaldesleukin (bempeg

Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator's choice of sunitinib or

Mechanisms of cooperative response to bempegaldesleukin (BEMPEG) and Y-90-NM600 targeted radionuclide

PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine

009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

为您找到相关结果约25个

共25条页码: 1/2页15条/页